KalVista Pharmaceuticals Inc (NASDAQ: KALV) kicked off on Friday, up 3.34% from the previous trading day, before settling in for the closing price of $8.09. Over the past 52 weeks, KALV has traded in a range of $8.07-$16.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -24.26% over the past five years. While this was happening, its average annual earnings per share was recorded -5.49%. With a float of $34.67 million, this company’s outstanding shares have now reached $43.27 million.
Let’s look at the performance matrix of the company that is accounted for 150 employees. In terms of profitability, gross margin is 46.1%, operating margin of -14231.51%, and the pretax margin is -12967.58%.
KalVista Pharmaceuticals Inc (KALV) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of KalVista Pharmaceuticals Inc is 29.84%, while institutional ownership is 74.28%. The most recent insider transaction that took place on Dec 09 ’24, was worth 74,363. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 7,627 shares at a rate of $9.75, taking the stock ownership to the 274,596 shares. Before that another transaction happened on Nov 26 ’24, when Company’s CHIEF MEDICAL OFFICER sold 2,187 for $9.87, making the entire transaction worth $21,586. This insider now owns 97,012 shares in total.
KalVista Pharmaceuticals Inc (KALV) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.54% during the next five years compared to -20.06% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Take a look at KalVista Pharmaceuticals Inc’s (KALV) current performance indicators. Last quarter, stock had a quick ratio of 6.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.64, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -2.63 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
KalVista Pharmaceuticals Inc (NASDAQ: KALV) saw its 5-day average volume 0.64 million, a positive change from its year-to-date volume of 0.48 million. As of the previous 9 days, the stock’s Stochastic %D was 12.72%. Additionally, its Average True Range was 0.63.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 5.68%, which indicates a significant decrease from 17.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.43% in the past 14 days, which was lower than the 66.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.40, while its 200-day Moving Average is $11.67. Nevertheless, the first resistance level for the watch stands at $8.62 in the near term. At $8.87, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.20. If the price goes on to break the first support level at $8.04, it is likely to go to the next support level at $7.71. The third support level lies at $7.46 if the price breaches the second support level.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
The company with the Market Capitalisation of 426.92 million has total of 49,418K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -126,640 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -42,270 K.
